EGFR and non-small cell lung carcinoma: In 2019, Zheng and colleagues conducted a single‐arm study of upfront TRT concurrently with first‐line EGFR TKI (gefitinib: 1, erlotinib: 9) in 10 stage IV NSCLC patients with limited metastatic lesions (≤10) harboring TKI‐sensitive EGFR mutations (n = 4 exon 21 L858R mutation; n = 6 exon 19 deletions).